First Light Asset Management »

Neuropace shares owned by First Light Asset Management

Quarter-by-quarter ownership of Neuropace (NPCE) shares owned by First Light Asset Management from 13F filings

Historical chart of First Light Asset Management investment in Neuropace

Tip: Access up to 7 years of quarterly data

All positions including Neuropace held by First Light Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neuropace by First Light Asset Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $14M 1.4M 10.31
2025-06-30 $15M 1.4M 11.14
2025-03-31 $20M 1.6M 12.29

More positions owned by First Light Asset Management

Axogen Common Stocks (AXGN)
Performant Healthcare Common Stocks (PHLT)
Centessa Pharmaceuticals Common Stocks (CNTA)
Neogenomics Common Stocks (NEO)
Amylyx Pharmaceuticals Common Stocks (AMLX)
Crinetics Pharmaceuticals Common Stocks (CRNX)
Health Catalyst Common Stocks (HCAT)
Palvella Therapeutics Common Stocks (PVLA)
Twist Bioscience Corporation Common Stocks (TWST)
Lenz Therapeutics Common Stocks (LENZ)
Organogenesis Holdings Common Stocks (ORGO)
Atricure Common Stocks (ATRC)
Anaptys Bio Common Stocks (ANAB)
Si-bone Common Stocks (SIBN)
Cidara Therapeutics Common Stocks (CDTX)

View all positions for First Light Asset Management

Top funds holding Neuropace

Polar Capital Holdings
Soleus Capital Management
OrbiMed Advisors
Morgan Stanley
BlackRock
Vanguard Group
First Light Asset Management
Armistice Capital
Kent Lake PR
Driehaus Capital Management
Deutsche Bank Aktiengesellschaft
FMR
Geode Capital Management
State Street Corporation
Silvercrest Asset Management Group

View all funds holding Neuropace